158 related articles for article (PubMed ID: 27838121)
21. The HARMONY Trial: Combined Ranolazine and Dronedarone in the Management of Paroxysmal Atrial Fibrillation: Mechanistic and Therapeutic Synergism.
Reiffel JA; Camm AJ; Belardinelli L; Zeng D; Karwatowska-Prokopczuk E; Olmsted A; Zareba W; Rosero S; Kowey P;
Circ Arrhythm Electrophysiol; 2015 Oct; 8(5):1048-56. PubMed ID: 26226999
[TBL] [Abstract][Full Text] [Related]
22. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE).
Koren MJ; Crager MR; Sweeney M
J Am Coll Cardiol; 2007 Mar; 49(10):1027-34. PubMed ID: 17349881
[TBL] [Abstract][Full Text] [Related]
23. Ranolazine: A Contemporary Review.
Rayner-Hartley E; Sedlak T
J Am Heart Assoc; 2016 Mar; 5(3):e003196. PubMed ID: 26979079
[No Abstract] [Full Text] [Related]
24. Coronary artery disease: a dam in the river for ranolazine.
Head SJ; Kappetein AP
Lancet; 2016 Jan; 387(10014):100-2. PubMed ID: 26474812
[No Abstract] [Full Text] [Related]
25. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
Chaitman BR; Pepine CJ; Parker JO; Skopal J; Chumakova G; Kuch J; Wang W; Skettino SL; Wolff AA;
JAMA; 2004 Jan; 291(3):309-16. PubMed ID: 14734593
[TBL] [Abstract][Full Text] [Related]
26. Long-Term (3 Years) Outcomes of Ranolazine Therapy for Refractory Angina Pectoris (from the Ranolazine Refractory Registry).
Storey KM; Wang J; Garberich RF; Bennett NM; Traverse JH; Arndt TL; Schmidt CW; Henry TD
Am J Cardiol; 2020 Aug; 129():1-4. PubMed ID: 32540170
[TBL] [Abstract][Full Text] [Related]
27. Ranolazine After Incomplete Percutaneous Coronary Revascularization in Patients With Versus Without Diabetes Mellitus: RIVER-PCI Trial.
Fanaroff AC; James SK; Weisz G; Prather K; Anstrom KJ; Mark DB; Ben-Yehuda O; Alexander KP; Stone GW; Ohman EM
J Am Coll Cardiol; 2017 May; 69(18):2304-2313. PubMed ID: 28473136
[TBL] [Abstract][Full Text] [Related]
28. [Symptomatic coronary heart disease therapy: ranolazine reduces frequency of angina in diabetic patients].
MMW Fortschr Med; 2013 Mar; 155 Spec No 1(1):20. PubMed ID: 24260912
[No Abstract] [Full Text] [Related]
29. Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial.
Alexander KP; Weisz G; Prather K; James S; Mark DB; Anstrom KJ; Davidson-Ray L; Witkowski A; Mulkay AJ; Osmukhina A; Farzaneh-Far R; Ben-Yehuda O; Stone GW; Ohman EM
Circulation; 2016 Jan; 133(1):39-47. PubMed ID: 26555329
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial.
Wilson SR; Scirica BM; Braunwald E; Murphy SA; Karwatowska-Prokopczuk E; Buros JL; Chaitman BR; Morrow DA
J Am Coll Cardiol; 2009 Apr; 53(17):1510-6. PubMed ID: 19389561
[TBL] [Abstract][Full Text] [Related]
31. Ranolazine: a new option in the management of chronic stable angina.
Dobesh PP; Trujillo TC
Pharmacotherapy; 2007 Dec; 27(12):1659-76. PubMed ID: 18041887
[TBL] [Abstract][Full Text] [Related]
32. Ranolazine for the treatment of atrial fibrillation.
Rosa GM; Dorighi U; Ferrero S; Brunacci M; Bertero G; Brunelli C
Expert Opin Investig Drugs; 2015 Jun; 24(6):825-36. PubMed ID: 25872749
[TBL] [Abstract][Full Text] [Related]
33. Comparative Effectiveness of Ranolazine Versus Traditional Therapies in Chronic Stable Angina Pectoris and Concomitant Diabetes Mellitus and Impact on Health Care Resource Utilization and Cardiac Interventions.
Page RL; Ghushchyan V; Read RA; Hartsfield CL; Koch BR; Nair KV
Am J Cardiol; 2015 Nov; 116(9):1321-8. PubMed ID: 26358510
[TBL] [Abstract][Full Text] [Related]
34. Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study.
Melloni C; Newby LK
Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):9-16. PubMed ID: 18095903
[TBL] [Abstract][Full Text] [Related]
35. Ranolazine: an antianginal drug with antiarrhythmic properties.
Tamargo J; Caballero R; Delpón E
Expert Rev Cardiovasc Ther; 2011 Jul; 9(7):815-27. PubMed ID: 21809962
[TBL] [Abstract][Full Text] [Related]
36. Ranolazine for the management of coronary artery disease.
Cheng JW
Clin Ther; 2006 Dec; 28(12):1996-2007. PubMed ID: 17296457
[TBL] [Abstract][Full Text] [Related]
37. Effects of ranolazine on various outcomes in patients with stable angina: an updated meta-analysis.
Manolis A; Kallistratos M; Poulimenos L; Zamfir T; Thomopoulos C
Hellenic J Cardiol; 2023; 71():26-32. PubMed ID: 36481415
[TBL] [Abstract][Full Text] [Related]
38. Should ranolazine be used for all patients with ischemic heart disease or only for symptomatic patients with stable angina or for those with refractory angina pectoris? A critical appraisal.
Thadani U
Expert Opin Pharmacother; 2012 Dec; 13(17):2555-63. PubMed ID: 23121448
[TBL] [Abstract][Full Text] [Related]
39. Ranolazine: Drug overview and possible role in primary microvascular angina management.
Cattaneo M; Porretta AP; Gallino A
Int J Cardiol; 2015 Feb; 181():376-81. PubMed ID: 25555283
[TBL] [Abstract][Full Text] [Related]
40. Ranolazine and late cardiac sodium current--a therapeutic target for angina, arrhythmia and more?
Makielski JC; Valdivia CR
Br J Pharmacol; 2006 May; 148(1):4-6. PubMed ID: 16520741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
